RESEARCH AGREEMENT



      This RESEARCH AGREEMENT (this "Agreement") is entered into as of March 5,

2003 (the "Effective Date") by and between Interleukin Genetics, Inc., a

Delaware corporation having its principal office at 135 Beaver Street, Waltham,

MA 02452 ("IG") and Access Business Group LLC, having its principal office at

7575 Fulton Street, East, Ada, Michigan 49355-0001 ("Access"). Each of IG and

Access is sometimes referred to individually herein as a "Party" and

collectively as the "Parties."



      WHEREAS, Access, together with its Affiliates, has expertise and

experience in the development, commercialization and marketing of nutritional

supplements and skin care products and IG has expertise and experience in

analyzing the effect of variations in genes related to inflammation, including

the effect of such variations on the risk for [ * ] and [ * ] disease, and

determining, through genetic profiling, individuals who may benefit from

specific interventions to promote health;



      WHEREAS, Access desires that IG perform the Research Program on the terms

and subject to the conditions set forth in this Agreement and in accordance with

the Protocol and the Parties desire to obtain certain rights to inventions

arising out of the Research Program; and



      WHEREAS, IG is willing to perform the Research Program and the Parties are

willing to grant each other such rights as described herein.



      NOW, THEREFORE, in consideration of the mutual covenants contained herein,

and for other good and valuable consideration, the Parties hereby agree as

follows:



1. DEFINITIONS



      Whenever used in this Agreement with an initial capital letter, the terms

defined in this Section 1 shall have the meanings specified.



      1.1 "AFFILIATE" means any corporation, firm, partnership or other entity

that directly or indirectly controls or is controlled by or is under common

control with a Party to this Agreement. For purposes of this definition,

"control" means ownership, directly or through one or more Affiliates, of fifty

percent (50%) or more of the shares of stock entitled to vote for the election

of directors, in the case of a corporation, fifty percent (50%) or more of the

equity interests in the case of any other type of legal entity, status as a

general partner in any partnership, or any other arrangement whereby a Party

controls or has the right to control the Board of Directors or equivalent

governing body of a corporation or other entity. For purposes of this Agreement,

Access, Alticor, Inc and subsidiaries of Alticor, Inc, on the one hand, and IG,

on the other hand, will not be deemed to be Affiliates of each other.



      1.2 "ACCESS PATENT RIGHTS" means any Patent Rights with respect to Access

Technology.

{PAGE}

CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.



      1.3 "ACCESS PROPRIETARY MATERIALS" means any Proprietary Materials of

Access that are used by Access, or provided by Access for use, in the Research

Program.



      1.4 "ACCESS TECHNOLOGY" means any Technology Controlled by Access as of

the Effective Date and during the Term that is used by Access, or provided by

Access for use, in the Research Program.



      1.5 "[ * ] TEST" means an analytic test performed on a [ * * ] or [ * ] to

[ * * * * ] to the use of a Dermagenomics Consumable or a Nutrigenomics

Consumable.



      1.6 "CONFIDENTIAL INFORMATION" means, as regards a Party (the "Receiving

Party"), (i) all information produced or discovered by either Party under the

Research Program (including without limitation, compilations, data, formulae,

models, patent disclosures, procedures, processes, projections, protocols,

results of experimentation and testing, specifications, strategies and

techniques), and all tangible and intangible embodiments thereof of any kind

whatsoever (including, without limitation, apparatus, biological or chemical

materials, animals, cells, compositions, documents, drawings, machinery, patent

applications, records and reports) and (ii) all other information (including but

not limited to information about any element of Technology or a Party's

business) which is disclosed, whether in writing and marked as confidential at

the time of disclosure to the Receiving Party or customarily considered to be

confidential information or by oral disclosure reduced to a writing, by the

other Party (the "Disclosing Party") to the Receiving Party or to any of its

employees, consultants, Affiliates, licensees and sublicensees hereunder except

to the extent that the information described in this subsection (ii) (a) as of

the date of disclosure is demonstrably known to, or in the possession of, the

Receiving Party or its Affiliates, as shown by written documentation, other than

by virtue of a prior confidential disclosure by the Disclosing Party or its

Affiliates; (b) as of the date of disclosure is in, or subsequently enters, the

public domain, through no fault or omission of the Receiving Party or its

Affiliates; (c) as of the date of disclosure or thereafter is obtained by the

Receiving Party or its Affiliates from a Third Party free from any obligation of

confidentiality to the Disclosing Party and rightfully in possession of such

information or (d) is independently developed by or for the Receiving Party or

its Affiliates without reference to or in reliance upon any of the foregoing

information as demonstrated by competent written records.



      1.7 "CONTROL" OR "CONTROLLED" means (a) with respect to Technology (other

than Proprietary Materials) and/or Patent Rights, the possession by a party of

the ability to grant a license or sublicense of such Technology and/or Patent

Rights as provided herein without violating the terms of any agreement or

arrangement between such party and any third party and (b) with respect to

Proprietary Materials, the possession by a party of the ability to supply such

Proprietary Materials to the other party as provided herein without violating

the terms of any agreement or arrangement between such party and any third

party.



      1.8 "DERMAGENOMICS CONSUMABLE" means any nutritional supplement or skin

care product or topical delivery system [ * * * * * * * ] designed to produce a

positive health benefit and/or a positive appearance of skin (i) the

manufacture, use or sale of which would, absent the license or ownership rights

granted to ABG hereunder and under the License Agreement, infringe any claim

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC